ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Tangeretin protects against nodularin-R-induced hepatotoxicity by modulating oxidative stress, inflammation, and apoptosis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nodularin (NOD) is a cyanobacterial toxin that induces severe biochemical and structural alterations in the liver. This study aimed to investigate the protective effects of tangeretin (TAN) against NOD-R-induced hepatotoxicity by evaluating biochemical, oxidative stress, histopathological, and immunohistochemical alterations in a murine model. Fifty-six male mice were randomly allocated to four experimental groups (n = 14/group): Control, TAN, NOD-R, and TAN + NOD-R. The control, TAN, and NOD-R groups received intraperitoneal (i.p.) injections of 0.9% saline containing 0.1% dimethyl sulfoxide (DMSO), TAN (100 mg/kg b.w., 0.9% saline 0.1% DMSO), and NOD-R (15 µg/kg b.w., 0.9% saline), respectively, for 7 consecutive days. The TAN + NOD-R group was administered TAN (100 mg/kg b.w.) for 10 consecutive days and concurrently challenged with NOD-R (15 µg/kg b.w.) from days 4 to 10. At the end of the experimental period, blood samples were collected for the determination of serum aminotransferase activities and oxidative stress parameters, while liver tissues were examined for oxidative stress biomarkers, histopathological alterations, and immunohistochemical expression of tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS), caspase - 3, and proliferating cell nuclear antigen (PCNA). NOD-R exposure significantly increased serum aminotransferase activities and malondialdehyde (MDA) levels and significantly decreased glutathione (GSH) levels and superoxide dismutase (SOD) concentrations, as well as catalase (CAT) and glutathione peroxidase (GSH-Px) activities. Moreover, NOD-R administration induced marked histopathological alterations and significantly increased hepatic expression of TNF-α, iNOS, caspase - 3, and PCNA. On the other hand, TAN pretreatment significantly alleviated NOD-R-induced hepatotoxicity by decreasing aminotransferase activities and MDA levels, restoring antioxidant defenses, attenuating histopathological changes, and downregulating the expression of TNF-α, iNOS, caspase - 3, and PCNA. The findings of this study indicated that TAN can be considered a protective agent against oxidative stress and NOD-R-induced hepatotoxicity.
Indexed as
Identifiers
42909587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.